Should you buy Theravance Biopharma stock? (NasdaqGM:TBPH). Let's see how it does in our automated value investing analysis system.
(Theravance Biopharma stock price per share)
|PE Ratio versus Sector||100% lower than other Healthcare stocks|
|PE Ratio versus Industry||100% lower than other Biotechnology stocks|
|Free Cash Flow Jitter||10%|
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 2,605,670 shares shorted. With 44,923,324 shares available for purchase and an average trading volume over the past 10 trading days of 1,071,900, it would take at least 2.431 days for all of the short holders to cover their shorts.
Based on our analysis, we believe that you should not buy Theravance Biopharma right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.
Does Theravance Biopharma have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
Most Popular Articles